Ryan Cawood, CEO of Oxford Genetics
Portfolio company, Oxford Genetics Limited ("Oxford Genetics"), has successfully negotiated six licensing deals for its scalable gene therapy manufacturing technologies in the last twelve months.
Oxford Genetics operates in the synthetic biology sector providing world leading technologies and advanced techniques for drug and gene therapy development. Grown from the foundations of patented DNA engineering methods, the company now offers a suite of novel solutions for gene therapy drug discovery, antibody therapy development and CRISPR gene editing.
The past year has seen Oxford Genetics achieve significant market traction, working extensively with high profile, global businesses within the biotechnology industry. The projects being undertaken have strengthened the portfolio of solutions and licensable technologies in the key areas of drug and gene therapy development services. You can read the full RNS REACH here.